Judaisation in the first Hebrew translation of Romeo and Juliet

Ram and Jael (Salkinson 1878), the earliest Hebrew version of Romeo and Juliet, is a highly domesticating translation containing numerous Jewish cultural elements. This is attributable to the fact that the translation formed part of an ideologically loaded Jewish Enlightenment initiative to establish a European-style literary canon in Hebrew and reflecting Jewish values at a time when the language was still almost solely a written medium prior to its late nineteenth-century re-vernacularisation in Palestine. This chapter discusses the unusual sociolinguistic background to Ram and Jael and analyses its main Judaising features, which include the treatment of non-Jewish names; holidays and rituals; establishments; oaths and expressions; mythological figures; and foreign languages, as well as the insertion of biblical verses

Understanding business process management: implications for theory and practice

Draft version published as a discussion paper. Final version published in British Journal of Management © British Academy of Management. Available online at http://onlinelibrary.wiley.com/This paper presents an empirically validated framework of business process management (BPM) to enable the pursuit of BPM theory. Phase 1 of the research focused on the development of an initial framework of BPM, derived from a synthesis of current literature. This comprised five key themes, subsequently categorized as 'application components' of BPM. The empirical validation of the framework was approached through case-based research, utilizing semi-structured interviews with managers of a large financial services organization, to explore the dimensions of the framework. The results suggest that, in addition to confirming the five 'application components' of the initial framework, three additional 'conceptual components' are important. These concepts differentiate BPM from other process management activities, and suggest that developing a prerequisite 'process mindset' is a fundamental component of a BPM approach

Pathogenic mechanisms and clinical implications of congenital neutropenia syndromes

Purpose of reviewThe purpose of this review is to summarize pathogenic mechanisms and clinical implications of the most illustrative genetic entities of congenital neutropenia syndromes.Recent findingsCongenital neutropenia comprise monogenetic entities with or without additional immunologic and extrahaematopoietic syndromatic features. Continuous careful explorations of known entities such as ELANE, GFI1, HAX1, G6PC3 deficiency and XLN help to define principles controlling differentiation and function of neutrophil granulocytes. Furthermore, the identification of novel genetic defects associated with congenital neutropenia, such as VPS45 deficiency, broadens our understanding of neutrophil biology. Pathogenic mechanisms imply protein and vesicle mistrafficking, endoplasmic reticulum stress, the unfolded protein response, destabilization of the mitochondrial membrane potential, disturbed energy metabolism, dysglycosylation and deregulated actin polymerization.SummaryAdvanced genetic and biochemical techniques have helped to expand our knowledge of congenital neutropenia syndromes. Known and novel genetic entities shed light on fundamental biological processes important for the homeostatis and functioning not only of the neutrophil granulocyte but as well of the entire haematopoietic system. Furthermore, treatment decisions become more tailored and might pave the road towards personalized molecular medicine

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

Professional Ethics for School Psychologists: A Problem-Solving Casebook

Ethical decision making forms the foundation of school psychological practice and is essential to protecting the rights of children and families. It both shapes daily delivery of school psychological services and informs decisions regarding specific ethical dilemmas. Every school psychologist needs to know not only what ethical principles guide the profession but also how to apply those principles to their work. Professional Ethics for School Psychologists: A Problem-Solving Casebook is the first comprehensive resource to illustrate how school psychologists can effectively identify, interpret, and put in practice the field’s ethical principles.https://digitalcommons.winthrop.edu/facultybookgallery/1000/thumbnail.jp